MedTrace Logo

Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors

NCT04795570 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-03-12

No results posted yet for this study

Summary

There is currently no prognostic or predictive risk marker for this urethral stricture disease.

The most conservative standard treatment for urethral stricture (internal urethrotomy) has a very high recurrence rate (greater than 75%) and, on many occasions, reconstructive urologists have to choose within a great variety of further complex interventions. Knowing risk and predictive markers of this disease could help to optimize both the need and the approach for these surgeries and may offer a more individualized management to patients.

Conditions

  • Urethral Stricture, Male
  • Hormone Deficiency
  • Fibrosis

Interventions

PROCEDURE

Transurethral resection of the prostate or bladder

All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.

Sponsors & Collaborators

  • Instituto de Investigación Biosanitaria de Granada (ibs.Granada)

    collaborator UNKNOWN

  • University Hospital Virgen de las Nieves

    lead OTHER

Principal Investigators

  • Ignacio Puche-Sanz, MD PhD · University Hospital Virgen de las Nieves

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-09-01
Completion
2022-09-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04795570 on ClinicalTrials.gov